19th Feb 2020 10:11
(Alliance News) - SkinBioTherapeutics PLC on Wednesday said its subsidiary AxisBiotix Ltd has signed a development agreement with Winclove Probiotics BV.
The AIM-listed life science company said the companies collaborated to help manage the symptoms associated with the skin condition, psoriasis. SkinBioTherapeutics and Winclove will design and develop a probiotic blend of "good" bacterial strains, based on the modifying properties of specific bacterial species on known psoriasis disease pathways.
Psoriasis is a debilitating skin condition caused by a malfunction of the immune system whereby skin cells are replaced more quickly than normal.
This blend will be developed into a probiotic food supplement which will be called AxisBiotix, SkinBioTherapeutics noted.
The Macclesfield, UK-headquartered company said it will be responsible for the identification and selection of the bacterial strains and patient testing, while Winclove will be responsible for the formulation and manufacture of AxisBiotix.
The development agreement was initially signed for three years but can be extended by mutual agreement, SkinBioTherapeutics said.
"We believe that in this partnership with Winclove, which was initiated by our Chief Scientific Officer Cath O'Neill, we can create a specific probiotic food supplement that has the potential to help manage the hard-to-treat symptoms of psoriasis," said SkinBioTherapeutics Chief Executive Stuart Ashman.
"We are very excited to help SkinBioTherapeutics develop and bring to market together a new probiotic formulation for such an innovative scientific area as the gut-skin axis with the potential to enhance the quality of life for people with difficult to treat skin conditions like psoriasis," added Winclove CEO Maarten Pekelharing.
SkinBioTherapeutics shares were trading 6.4% lower in London at 11.70 pence each.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Skinbiotherap.